Cytokinetics | CYTK - Cash And Equivalent


Cytokinetics reported $225.47M in Cash and Equivalent for its fiscal quarter ending in September of 2025.





Cash And Equivalent Change Date
Acadia Pharmaceuticals USD 819.69M 27.33M Dec/2025
Amgen USD 9.13B 316M Dec/2025
Arca Biopharma USD 91.25M 25.86M Sep/2025
Bayer EUR 5.9B 1.34B Sep/2025
Biogen USD 3.01B 854.3M Dec/2025
Brainstorm Cell Therapeutics USD 5K 819K Sep/2025
Bristol-Myers Squibb USD 10.21B 5.52B Dec/2025
Capricor Therapeutics USD 19.51M 3.73M Sep/2025
Cytokinetics USD 225.47M 150.53M Sep/2025
Eisai JPY 301.65B 16.27B Sep/2025
Eli Lilly USD 7.27B 2.52B Dec/2025
Exelixis USD 482.49M 106.19M Dec/2025
Geron USD 79.44M 553K Dec/2025
Halozyme Therapeutics USD 133.82M 285.84M Dec/2025
Ionis Pharmaceuticals USD 2.68B 437M Dec/2025
Ligand Pharmaceuticals USD 664.52M 596.85M Sep/2025
Merck USD 18.17B 10.16B Sep/2025
Novartis USD 9.56B 2.9B Sep/2025
Pfizer USD 1.34B 295M Sep/2025
Regeneron Pharmaceuticals USD 18.87B 16.36B Dec/2025
Roche Holding CHF 7.55B 579M Jun/2025
Sanofi EUR 7.66B 1.25B Dec/2025